Welcome to our dedicated page for Vicore Pharma Hldg AB SEC filings (Ticker: VCRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Vicore Pharma Hldg AB's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Vicore Pharma Hldg AB's regulatory disclosures and financial reporting.
Vicore Pharma Holding has appointed Rob Slack, PhD, FRSB as Chief Scientific Officer, succeeding Johan Raud, MD, PhD, who will transition to Senior Advisor. Dr. Slack brings over 20 years of leadership in fibrosis and respiratory translational science, including senior roles at GSK as Vice President and Head of Respiratory Biology and prior service as acting Chief Scientific Officer at Galecto. He has contributed to multiple approved respiratory medicines for asthma, COPD and IPF and has more than 60 scientific publications. As Chief Scientific Officer, he will lead Vicore’s research strategy and development of its next-generation angiotensin II type 2 receptor agonist pipeline, including the lead program buloxibutid, which is in a global 52‑week Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis and holds Orphan Drug and Fast Track designations from the U.S. FDA.